Sandoz To Acquire Retinal Disease Biosimilar For $170M
Sandoz Group AG said on Monday that it will buy a therapy for retinal diseases from U.S. biopharmaceutical company Coherus BioSciences Inc. for $170 million in cash, as the Swiss-German generic drugs...To view the full article, register now.
Already a subscriber? Click here to view full article